ISOCITRATE DEHYDROGENASE 2 (IDH2) INHIBITOR
Idhifa is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat relapsed or refractory acute myeloid leukemia (AML) that has tested positive for a mutation in the isocitrate dehydrogenase-2 (IDH2) gene. Idhifa may also be referred to by its drug name, enasidenib.
Idhifa is the first drug in a class called IDH2 inhibitors. Idhifa is believed to work by interfering with the ability of leukemia cells to release stored energy.
How do I take it?
Idhifa is taken orally once a day.
Idhifa comes in the form of a tablet.
The FDA-approved label for Idhifa lists common side effects including nausea, vomiting, elevated bilirubin (impaired liver metabolism), diarrhea, and loss of appetite.
Rare but serious side effects listed for Idhifa include fetal harm in pregnant women and differentiation syndrome, a life-threatening condition that causes trouble breathing and hypotension (low blood pressure).
For more details about this treatment, visit:
Idhifa — Celgene
AML: Chemotherapy and Drug Therapy — Leukemia and Lymphoma Society
AML: Relapsed and Refractory — Leukemia and Lymphoma Society